Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Transplant Cell Ther. 2022 Oct;28(10):677.e1-677.e6. doi: 10.1016/j.jtct.2022.06.022. Epub 2022 Jul 6.
During the COVID-19 pandemic, donor grafts are frequently cryopreserved to ensure that a graft is available before starting a conditioning regimen. However, there have been conflicting reports on the effect of cryopreservation on transplantation outcomes. Also, the impact of cryopreservation may differ in bone marrow (BM) transplantation (BMT) and peripheral blood stem cell (PBSC) transplantation (PBSCT). In this retrospective study, we analyzed the clinical data of both cryopreserved unrelated BMTs (n = 235) and PBSCTs (n = 118) and compared these with data from a large control cohort without cryopreservation including 4133 BMTs and 720 PBSCTs. Among the patients with cryopreserved grafts, 10 BMT recipients (4.3%) and 3 PBSCT recipients (2.5%) did not achieve neutrophil engraftment after transplantation, including 4 of the former and all 3 of the latter who died early before engraftment. In a multivariate analysis, cryopreservation was not associated with neutrophil engraftment in BMT but significantly delayed neutrophil engraftment in PBSCT (hazard ratio [HR], .82; 95% confidence interval [CI], .69 to .97; P = .023). There was an interaction with borderline significance between cryopreservation and the stem cell source (P = .067). Platelet engraftment was delayed by cryopreservation after both BMT and PBSCT. Only 2 cryopreserved grafts (<1%) were unused during the study period. The cryopreservation of unrelated donor BM and PBSC grafts is associated with a slight delay in neutrophil and platelet engraftment but an acceptable rate of graft failure. PBSC grafts may be more sensitive to cryopreservation than BM grafts. Cryopreservation is a reasonable option during COVID-19 pandemic, provided that the apheresis and transplantation centers are adept at cryopreservation. © 2022 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
在 COVID-19 大流行期间,为了确保在开始预处理方案之前有可供使用的移植物,供体移植物经常被冷冻保存。然而,冷冻保存对移植结果的影响存在相互矛盾的报道。此外,冷冻保存的影响在骨髓(BM)移植(BMT)和外周血干细胞(PBSC)移植(PBSCT)中可能不同。在这项回顾性研究中,我们分析了冷冻保存的无关 BMT(n=235)和 PBSCT(n=118)的临床数据,并将这些数据与未冷冻保存的大型对照队列(包括 4133 例 BMT 和 720 例 PBSCT)的数据进行了比较。在有冷冻保存移植物的患者中,10 例 BMT 受者(4.3%)和 3 例 PBSCT 受者(2.5%)在移植后未获得中性粒细胞植入,其中 4 例前者和所有 3 例后者在植入前因早期死亡。在多变量分析中,冷冻保存与 BMT 的中性粒细胞植入无关,但显著延迟了 PBSCT 的中性粒细胞植入(风险比[HR],0.82;95%置信区间[CI],0.69 至 0.97;P=0.023)。冷冻保存与干细胞来源之间存在边缘显著的相互作用(P=0.067)。冷冻保存后,BMT 和 PBSCT 均延迟血小板植入。在研究期间,只有 2 例冷冻保存的移植物(<1%)未使用。冷冻保存无关供体 BM 和 PBSC 移植物与中性粒细胞和血小板植入略有延迟相关,但移植物失败率可接受。与 BM 移植物相比,PBSC 移植物可能对冷冻保存更敏感。只要单采和移植中心擅长冷冻保存,在 COVID-19 大流行期间,冷冻保存是一个合理的选择。©2022 美国移植和细胞治疗学会。由 Elsevier Inc. 出版。